Clinical significance of fragmented QRS complexes or J waves in patients with idiopathic ventricular arrhythmias

PLoS One. 2018 Apr 25;13(4):e0194363. doi: 10.1371/journal.pone.0194363. eCollection 2018.

Abstract

Background: Idiopathic ventricular fibrillation (IVF) can cause sudden cardiac death. Previous studies have reported that J waves and fragmented QRS complexes (f-QRS) are arrhythmogenic markers and predictors of cardiac events. We evaluated the prevalence and clinical significance of J waves and f-QRS in patients with IVF.

Methods: We studied 81 patients who received an implantable cardioverter defibrillator (ICD) due to IVF between October 1999 and June 2015. We assessed the prevalence of J waves and f-QRS using electrocardiograms (ECGs). Patients were classified into three groups: J wave group (n = 35), f-QRS group (n = 20), or normal ECG group (n = 26). The control group included 81 subjects without heart disease who were matched for age, sex, and race. We compared syncope, sudden cardiac arrest, and appropriate ICD shock between the three groups.

Results: The follow-up duration was 4.1 years. J waves and f-QRS were more frequent in patients with IVF than in control subjects (43.2%, 21% vs. 24.7%, 19.7%, P < 0.001). Out of the three groups, clinical cardiac events were most frequent in the f-QRS group (50% vs. 45.7% vs. 11.5%, P = 0.028). A comparison of the combined group of J wave and f-QRS versus the normal ECG group revealed that the combined group had a higher frequency of clinical cardiac events than the normal ECG group (47.3% vs. 11.5%, respectively, P = 0.009).

Conclusions: Patients with IVF had higher prevalence of f-QRS or J waves. And patients with f-QRS or J waves were at higher risk of recurrent ventricular fibrillation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Arrhythmia Agents / therapeutic use
  • Case-Control Studies
  • Defibrillators, Implantable
  • Electrocardiography*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prevalence
  • Ventricular Fibrillation / diagnosis*
  • Ventricular Fibrillation / epidemiology
  • Ventricular Fibrillation / physiopathology*
  • Ventricular Fibrillation / therapy
  • Young Adult

Substances

  • Anti-Arrhythmia Agents

Supplementary concepts

  • Paroxysmal ventricular fibrillation

Grants and funding

This study was supported by an unrestricted research grant from the Samsung Biomedical Research Institute (grant no. SMO1170431) to YKO. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.